Regen has had major breakthroughs and great results with their new drug HemaXellerate during "Human" clinical trials for the treatment of aPlastic Anemia, a rare blood disease. They have also during this process discovered a new, much larger market for HemaXellerate. $RGBP has discovered that HemaXellerate is effective in treating Bone Marrow Suppression, a very painful condition as a result of chemo therapy.
The bigger news is that $RGBP has advanced further than any Bio Tech Stem Cell in Pre Clinical trials with NR2F6. Analogues Have Been Synthesized for Lead Compounds and are Complete, now the Optimization Process is set to Begin Utilizing NR2F6 Protein Molecules. Regen BioPharma, has reported that they have synthesized more than 30 analogues of our initial small molecules and during this process have uncovered and identified a dynamic new chemical compound series that modulates NR2F6. A particularly active series of NR2F6 activators, which are not toxic and have an ability to activate NR2F6 approximately 10 times more effectively than seen with our previous series.
NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists, which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity. This is again very similar to IMF Therapeutics oncology space.
Bristol Myers Squibb (BMS) just announced today a $2.3 Billion acquisition of IMF Therapeutics. With what Regen is accomplishing with NR2F6, one has to think, one day, someone, a much larger Pharma company will come knocking on $RGBP's door.
David Koos (CEO) of Regen - Addresses Potential Impact of Recent Bristol Myers Squibb (BMS) $2.3 Billion Acquisition of IMF Therapeutics and similarities.
